Conatus Pharmaceuticals, Inc. (CNAT)

Conatus-Pharma-logoConatus Pharmaceuticals, Inc. is a biotechnology company that develops and commercializes novel medicines for the treatment of liver disease. Conatus develops emracasan, the company’s lead compound for treating patients suffering from chronic liver disease, as well as acute exacerbations of chronic liver disease. An orally active pan-caspase protease inhibitor, emracasan is designed for reduction of the activity of ten human caspases, the enzymes mediating inflammation and death of cells, or apoptosis.

The company believes that emracasan has the capability to interrupt the progress of liver disease, and can provide options for treatment in various areas of liver disease based on the preclinical and clinical trial results suggesting that emracasan has the potential to slow the progression of liver disease, regardless of its original cause. Emracasan has been studied in ten clinical trials with more than 500 subjects.

In the Phase 2b of clinical trial in liver disease patients, emracasan has demonstrated a consistent, rapid, significant, and sustained reduction of elevated levels of alanine aminotransferase (ALT) and cleaved Cytokeratin 18 (cCK18), the two key biomarkers of cell death and inflammation that are implicated in the progression and severity of liver disease.

Conatus Pharmaceuticals, Inc. has designed a clinical program demonstrating emracasan’s therapeutic benefits across the spectrum of fibrotic liver disease. The company’s strategy focuses on targeting of indications for emracasan in small patient populations, including the small population of patients with chronic liver failure (CLF), and acute-on-chronic liver failure (ACLF).

Conatus Pharmaceuticals, Inc. is traded in the OTC markets under the stock symbol CNAT. The company is committed to serving the best interests of their shareholders. They provide key shareholder information and financial reports to help put the company’s financial performance into perspective.

Yahoo! Finance: CNAT News

Latest Financial News for CNAT

Conatus (CNAT) Stock Price Could Hit Zero

Did an iceberg just wallop into Conatus (CNAT) stock? This biotech company's shares plunged yesterday at breakneck speed of almost 70%. The reason? Conatus’ lead drug Emricasan failed a mid-stage trial in patients with nonalcoholic steatohepatitis-related decompensated cirrhosis.Emricasan – an oral pan-caspase inhibitor that targets nonalcoholic steatohepatitis – has gone through several trials over the last three years. This recent phase 2b trial was conclusive enough for Conatus to forgo any further testing, after the trial clearly proved the drug is not an effective treatment.Amidst uncertainty about Conatus’ strategic options, H.C. Wainwright analyst Ed Arce has removed his price target on CNAT stock, while maintaining a Neutral rating. (To watch Arce's track record, click here)Conatus projects its cash and equivalents at the end of 2019 to be in the range of $10M to $15M. The company also announced that 40% of their staff were laid off after the failure and suspension of the 2b trial.Arce believes that it is incredibly challenging to value the company during this period of cash preservation and strategic re-evaluation. With the termination of the development program for Emricasan, Conatus is currently focused on finding a strategic purchaser who sees value in the CTS-2090 compound used in Emricasan and the expertise of the remaining employees. With a market cap of $9.64M, it appears that the market is pricing in the possibility of bankruptcy, as the company is being valued below Conatus’ projections of end-of-year 2019 cash and equivalents.Arce believes the main concern is that if the company cannot find a strategic acquirer before their cash runs dry, they are at seriously risk of going into bankruptcy.TipRanks suggests caution roars loud on Wall Street for sell-side analysts sizing up the challenged drug maker's prospects. Out of 4 analysts polled in the last 12 months, all 4 are sidelined on CNAT stock. (See CNAT's price targets and analyst ratings on TipRanks) More recent articles from Smarter Analyst: * Tesla (TSLA) Scrambles to Restore Faith; Wedbush Remains Cautions on the Stock * Micron (MU) Stock Has a New Bull * Has Roku Stock Price Hit Its Peak? * Will Qualcomm (QCOM) Stock Win Again? Canaccord Remains Bullish

Biotech Stock Roundup: Vertex, AMAG Drugs Get FDA Nod, Conatus Study Fails & More

Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 25) ArQule, Inc. (NASDAQ: ARQL ) Zai Lab Ltd (NASDAQ: ZLAB ...

Conatus' Emricasan Lags Primary Goal in Liver Function Study

Conatus' (CNAT) emricasan fails to meet the primary endpoint in the phase IIb ENCORE-LF study on decompensated NASH cirrhosis patients while the ENCORE-PH probe falls shy of the predefined objectives.

NASH Disappointment Forces Conatus To Explore Strategic Alternatives

Shares of micro-cap biotech Conatus Pharmaceuticals Inc (NASDAQ: CNAT) were sinking further into penny stock territory Tuesday after two announcements made Monday after the market close. Conatus said it has engaged Oppenheimer to explore strategic alternatives in a bid to enhance shareholder value.